- Home
- HCAI vs CLRB Comparison
HCAI vs CLRB Comparison
Compare HCAI & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HCAI | CLRB |
|---|---|---|
| Founded | 2004 | 2002 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.7M | 12.9M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | HCAI | CLRB |
|---|---|---|
| Price | $0.21 | $2.90 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 415.5K | 24.7K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $63.07 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $0.23 |
| 52 Week High | $10.97 | $10.19 |
Technical Indicators
Market Signals| Indicator | HCAI | CLRB |
|---|---|---|
| Relative Strength Index (RSI) | 37.07 | 41.48 |
| Support Level | $0.20 | $2.81 |
| Resistance Level | $0.44 | $3.60 |
| Average True Range (ATR) | 0.02 | 0.24 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 31.45 | 21.20 |
Price Performance
Historical ComparisonAbout HCAI Huachen AI Parking Management Technology Holding Co. Ltd. Ordinary Shares
Huachen AI Parking Management Technology Holding Co Ltd is a comprehensive smart parking solutions and equipment structural parts provider. The company manufactures and offer various cubic parking garage products by employing various working principles, such as lifting and shifting, convenient lifting, vertical circulation, vertical lifting, plane moving, alley stacking, multi-layer cycle, horizontal cycle, and car lift.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.